Company intelligence / Profile preview

Phoenix VA

San Antonio, Texas, USAva.gov ↗

Ownership: Private
Development stage: Other

Overview

Phoenix Biotechnology has developed an antiviral product based on oleandrin, a compound extracted from Nerium oleander. Their research suggests this compound disrupts viral envelope formation, rendering viruses non-infective. The approach is positioned as a broad-spectrum antiviral platform with potential applicability against multiple viral pathogens and their mutations. There are no published results indicating successful completion of late-stage clinical trials or regulatory approval[1].

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePlant-derived extract
Industry: Biotech

Partnerships

Avila Herbals LLC (exclusive global manufacturing and R&D agreement)[1]

Beyond the preview

Go deeper on Phoenix VA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix VA.

Explore the full profile